Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again

Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Rese...

Descripción completa

Detalles Bibliográficos
Autor principal: Eisenberg, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526641/
https://www.ncbi.nlm.nih.gov/pubmed/16732895
http://dx.doi.org/10.1186/ar1967
_version_ 1782128931042754560
author Eisenberg, Robert
author_facet Eisenberg, Robert
author_sort Eisenberg, Robert
collection PubMed
description Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Research & Therapy suggests that epratuzumab may be safe and efficacious for systemic lupus erythematosus. A randomized controlled trial is currently active to test this possibility.
format Text
id pubmed-1526641
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15266412006-08-04 Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again Eisenberg, Robert Arthritis Res Ther Commentary Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Research & Therapy suggests that epratuzumab may be safe and efficacious for systemic lupus erythematosus. A randomized controlled trial is currently active to test this possibility. BioMed Central 2006 2006-05-15 /pmc/articles/PMC1526641/ /pubmed/16732895 http://dx.doi.org/10.1186/ar1967 Text en Copyright © 2006 BioMed Central Ltd
spellingShingle Commentary
Eisenberg, Robert
Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title_full Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title_fullStr Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title_full_unstemmed Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title_short Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
title_sort targeting b cells in systemic lupus erythematosus: not just déjà vu all over again
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526641/
https://www.ncbi.nlm.nih.gov/pubmed/16732895
http://dx.doi.org/10.1186/ar1967
work_keys_str_mv AT eisenbergrobert targetingbcellsinsystemiclupuserythematosusnotjustdejavualloveragain

Ejemplares similares